Daniel Isquith

694 total citations
21 papers, 471 citations indexed

About

Daniel Isquith is a scholar working on Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Daniel Isquith has authored 21 papers receiving a total of 471 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cardiology and Cardiovascular Medicine, 10 papers in Pulmonary and Respiratory Medicine and 8 papers in Surgery. Recurrent topics in Daniel Isquith's work include Cerebrovascular and Carotid Artery Diseases (10 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (6 papers) and Cardiac Imaging and Diagnostics (6 papers). Daniel Isquith is often cited by papers focused on Cerebrovascular and Carotid Artery Diseases (10 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (6 papers) and Cardiac Imaging and Diagnostics (6 papers). Daniel Isquith collaborates with scholars based in United States, China and Canada. Daniel Isquith's co-authors include Xue-Qiao Zhao, Chun Yuan, Daniel S. Hippe, Jie Sun, Niranjan Balu, Thomas S. Hatsukami, Moni B. Neradilek, Kevin D. O’Brien, Gádor Cantón and Tomáš Vaisar and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and Arteriosclerosis Thrombosis and Vascular Biology.

In The Last Decade

Daniel Isquith

21 papers receiving 466 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Isquith United States	14	209	191	191	123	99	21	471
Yingling Zhou China	13	106 0.5×	271 1.4×	156 0.8×	48 0.4×	129 1.3×	33	521
Donato Moschetta Italy	14	92 0.4×	284 1.5×	98 0.5×	60 0.5×	83 0.8×	38	448
Fisnik Jashari Kosovo	11	238 1.1×	287 1.5×	114 0.6×	24 0.2×	121 1.2×	30	487
Cem Barçın Türkiye	11	116 0.6×	172 0.9×	135 0.7×	60 0.5×	43 0.4×	60	370
Kálmán Benke Hungary	14	146 0.7×	206 1.1×	191 1.0×	142 1.2×	39 0.4×	50	551
Elnur Alızade Türkiye	11	66 0.3×	302 1.6×	77 0.4×	62 0.5×	82 0.8×	62	461
Martin Græbe Denmark	13	317 1.5×	164 0.9×	72 0.4×	20 0.2×	98 1.0×	22	465
Adam Penkalla Germany	6	60 0.3×	272 1.4×	77 0.4×	88 0.7×	82 0.8×	17	444
Ming‐Lung Tsai Taiwan	15	39 0.2×	156 0.8×	153 0.8×	113 0.9×	53 0.5×	33	465

Countries citing papers authored by Daniel Isquith

Since Specialization

Citations

This map shows the geographic impact of Daniel Isquith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Isquith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Isquith more than expected).

Fields of papers citing papers by Daniel Isquith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Isquith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Isquith. The network helps show where Daniel Isquith may publish in the future.

Co-authorship network of co-authors of Daniel Isquith

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Isquith. A scholar is included among the top collaborators of Daniel Isquith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Isquith. Daniel Isquith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Naumova, Anna, Daniel Isquith, Niranjan Balu, et al.. (2024). Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure. Cardiovascular Diabetology. 23(1). 197–197. 26 indexed citations

Zhao, Xue-Qiao, Jie Sun, Daniel S. Hippe, et al.. (2022). Magnetic Resonance Imaging of Intraplaque Hemorrhage and Plaque Lipid Content With Continued Lipid-Lowering Therapy: Results of a Magnetic Resonance Imaging Substudy in AIM-HIGH. Circulation Cardiovascular Imaging. 15(11). e014229–e014229. 10 indexed citations

Sun, Jie, Norman E. Lepor, Gádor Cantón, et al.. (2021). Serial magnetic resonance imaging detects a rapid reduction in plaque lipid content under PCSK9 inhibition with alirocumab. International journal of cardiac imaging. 37(4). 1415–1422. 17 indexed citations

Lepor, Norman E., Jie Sun, Gádor Cantón, et al.. (2021). Regression in carotid plaque lipid content and neovasculature with PCSK9 inhibition: A time course study. Atherosclerosis. 327. 31–38. 16 indexed citations

Han, Tianwen, Pathmaja Paramsothy, Daniel Isquith, et al.. (2020). High-resolution MRI assessed carotid atherosclerotic plaque characteristics comparing men and women with elevated ApoB levels. International journal of cardiac imaging. 36(3). 481–489. 4 indexed citations

Hippe, Daniel S., Binh An P. Phan, Jie Sun, et al.. (2018). Lp(a) (Lipoprotein(a)) Levels Predict Progression of Carotid Atherosclerosis in Subjects With Atherosclerotic Cardiovascular Disease on Intensive Lipid Therapy. Arteriosclerosis Thrombosis and Vascular Biology. 38(3). 673–678. 33 indexed citations

Sun, Jie, Xue-Qiao Zhao, Niranjan Balu, et al.. (2017). Carotid Plaque Lipid Content and Fibrous Cap Status Predict Systemic CV Outcomes. JACC. Cardiovascular imaging. 10(3). 241–249. 79 indexed citations

Wu, Xing, Wen Su, Daniel Isquith, et al.. (2017). Low levels of ApoA1 improve risk prediction of type 2 diabetes mellitus. Journal of clinical lipidology. 11(2). 362–368. 20 indexed citations

Li, Weiping, Moni B. Neradilek, Daniel Isquith, et al.. (2017). Pregnancy-associated plasma protein-A is a stronger predictor for adverse cardiovascular outcomes after acute coronary syndrome in type-2 diabetes mellitus. Cardiovascular Diabetology. 16(1). 45–45. 8 indexed citations

10.

O’Brien, Kevin D., Daniel S. Hippe, Huijun Chen, et al.. (2016). Summary of clinical and laboratory data of study subjects with and without DCE-MRI plaque measurements in the AIM-HIGH clinical trial. Data in Brief. 6. 476–481. 2 indexed citations

11.

Zhao, Xue-Qiao, Binh An P. Phan, Joseph Davis, et al.. (2016). Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Treatment Study—Observational Study. Journal of clinical lipidology. 10(5). 1091–1097. 5 indexed citations

12.

Borja, Mark S., Angela D. Irwin, Daniel Isquith, et al.. (2015). HDL-apolipoprotein A-I exchange is independently associated with cholesterol efflux capacity. Journal of Lipid Research. 56(10). 2002–2009. 39 indexed citations

13.

O’Brien, Kevin D., Daniel S. Hippe, Huijun Chen, et al.. (2015). Longer duration of statin therapy is associated with decreased carotid plaque vascularity by magnetic resonance imaging. Atherosclerosis. 245. 74–81. 19 indexed citations

14.

Ronsein, Graziella E., Patrick M. Hutchins, Daniel Isquith, et al.. (2015). Niacin Therapy Increases High-Density Lipoprotein Particles and Total Cholesterol Efflux Capacity But Not ABCA1-Specific Cholesterol Efflux in Statin-Treated Subjects. Arteriosclerosis Thrombosis and Vascular Biology. 36(2). 404–411. 45 indexed citations

15.

Zhao, Xue, Joseph Davis, Daniel Isquith, et al.. (2014). MORTALITY REDUCTION IN PATIENTS TREATED WITH LONG-TERM INTENSIVE LIPID THERAPY: 20-YEAR FOLLOW-UP OF THE FAMILIAR ATHEROSCLEROSIS TREATMENT STUDY- OBSERVATIONAL STUDY. Journal of the American College of Cardiology. 63(12). A1287–A1287. 1 indexed citations

16.

Zhao, Xue, Thomas S. Hatsukami, Daniel S. Hippe, et al.. (2014). Clinical Factors Associated With High-Risk Carotid Plaque Features as Assessed by Magnetic Resonance Imaging in Patients With Established Vascular Disease (from the AIM-HIGH Study). The American Journal of Cardiology. 114(9). 1412–1419. 33 indexed citations

17.

Gill, Edward A., Michael A. Chen, Pathmaja Paramsothy, et al.. (2014). Abstract 12697: Omega-3 Fatty Acids Effects on Carotid IMT in Metabolic Syndrome. Circulation. 130. 2 indexed citations

18.

Sun, Jie, Xue-Qiao Zhao, Niranjan Balu, et al.. (2014). Carotid magnetic resonance imaging for monitoring atherosclerotic plaque progression: a multicenter reproducibility study. International journal of cardiac imaging. 31(1). 95–103. 47 indexed citations

19.

Phan, Binh An P., et al.. (2012). Effects of Niacin on Glucose Levels, Coronary Stenosis Progression, and Clinical Events in Subjects With Normal Baseline Glucose Levels (<100 mg/dl): A Combined Analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI During Lipid-Lowering (CPC) Study. The American Journal of Cardiology. 111(3). 352–355. 17 indexed citations

20.

Dang, Qianyu, et al.. (2009). Comparison of Sleep/Wake Behavior in CKD Stages 4 to 5 and Hemodialysis Populations Using Wrist Actigraphy. American Journal of Kidney Diseases. 53(4). 665–672. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact